Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ICCM Stock Forecast 2026-2027
$0.69
Current Price
$47.52M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ICCM Price Targets
+371.8%
To High Target of $3.25
+353.6%
To Median Target of $3.13
+335.5%
To Low Target of $3.00
ICCM Price Momentum
+9.5%
1 Week Change
+21.1%
1 Month Change
-50.0%
1 Year Change
+13.1%
Year-to-Date Change
-55.0%
From 52W High of $1.53
+27.6%
From 52W Low of $0.54
📊 TOP ANALYST CALLS
Did ICCM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IceCure is one of their latest high-conviction picks.
Latest ICCM Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ICCM has a bullish consensus with a median price target of $3.13 (ranging from $3.00 to $3.25). The overall analyst rating is N/A (N/A/10). Currently trading at $0.69, the median forecast implies a 353.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 335.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICCM Analyst Ratings
2
Buy
0
Hold
0
Sell
ICCM Price Target Range
Low
$3.00
Average
$3.13
High
$3.25
Current: $0.69
Latest ICCM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICCM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $2.50 |
| Aug 15, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $2.00 |
| May 29, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Mar 28, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Nov 27, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Nov 8, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Sep 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Aug 21, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $2.50 |
| Jul 2, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| May 29, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Apr 16, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Apr 4, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Mar 20, 2024 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $2.90 |
| Mar 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Nov 29, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Sep 6, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Aug 15, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $4.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
IceCure Medical Ltd. (ICCM) Competitors
The following stocks are similar to IceCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IceCure Medical Ltd. (ICCM) Financial Data
IceCure Medical Ltd. has a market capitalization of $47.52M with a P/E ratio of -2.3x. The company generates $2.98M in trailing twelve-month revenue with a 44.1% profit margin.
Revenue growth is +28.4% quarter-over-quarter, while maintaining an operating margin of -451.3% and return on equity of -157.9%.
Valuation Metrics
Market Cap
$47.52M
Enterprise Value
$32.66M
P/E Ratio
-2.3x
PEG Ratio
-10.2x
Price/Sales
14.2x
Growth & Margins
Revenue Growth (YoY)
+28.4%
Gross Margin
+32.6%
Operating Margin
-451.3%
Net Margin
+44.1%
EPS Growth
+28.4%
Financial Health
Cash/Price Ratio
+21.0%
Current Ratio
2.4x
Debt/Equity
3.1x
ROE
-157.9%
ROA
-63.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
IceCure Medical Ltd. (ICCM) Business Model
About IceCure Medical Ltd.
What They Do
Innovative cryoablation technology for cancer treatment.
Business Model
IceCure Medical Ltd. generates revenue through the sale of its cryoablation devices used in minimally invasive cancer treatments. The company targets healthcare providers, including hospitals and clinics, focusing on improving patient outcomes and safety while reducing recovery times. By offering a cutting-edge alternative to traditional surgical procedures, IceCure enhances its value proposition in the medical equipment market.
Additional Information
Based in Israel, IceCure is advancing its technology to cater to various cancer types, including breast, kidney, lung, bone, and liver cancers. The company emphasizes collaboration with medical professionals to broaden its market presence and improve treatment efficacy, positioning itself as a leader in the oncology segment of the medical device industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
64
CEO
Mr. Eyal Shamir
Country
Israel
IPO Year
2011
Website
www.icecure-medical.comIceCure Medical Ltd. (ICCM) Latest News & Analysis
Latest News
Quick Summary
IceCure Medical's FDA-approved "ChoICE Trial Post-Market Study" will assess ProSense® cryoablation for low-risk breast cancer, potentially enhancing commercial adoption and reimbursement opportunities.
Why It Matters
IceCure's FDA-approved post-market study for ProSense® could enhance market adoption, potentially increasing revenue and investor confidence in its cryoablation technology for breast cancer treatment.
Source: PRNewsWire
Market Sentiment:
Neutral
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
3 days ago
Quick Summary
IceCure Medical Ltd. (Nasdaq: ICCM) will release its financial and operational results for the year ended December 31, 2025, on March 17, 2026, before the market opens.
Why It Matters
IceCure Medical's upcoming financial results release may impact stock performance, reflecting the company's growth and operational efficiency in the competitive medical technology sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical's ProSense® cryoablation received a favorable FDA Advisory Panel vote for low-risk breast cancer. The ASBrS 2026 Resource Guide update supports its commercial adoption post-FDA clearance.
Why It Matters
The FDA's favorable vote on IceCure's ProSense® cryoablation and ASBrS guidance boosts market confidence, potentially increasing adoption and sales, positively impacting IceCure's stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical's ProSense® Cryoablation achieved a 92.9% reduction in fibroadenoma size one year post-treatment. This FDA-cleared method may influence treatment guidelines for non-cancerous breast tumors.
Why It Matters
The positive study results for ProSense® could lead to revised treatment guidelines, potentially increasing market adoption and revenue for IceCure Medical, impacting its stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical's ProSense® shows an 88.7% recurrence-free rate in treating kidney tumors. The technology is approved for use in multiple regions, addressing a growing global incidence of kidney cancer.
Why It Matters
Positive interim data for ProSense® suggests strong market potential amid rising kidney cancer rates, indicating a growing demand for innovative treatments. This could significantly impact IceCure Medical's stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IceCure Medical's ProSense® system for cryoablation has been purchased by Thomas Hospital in Alabama, marking the first use of this technology in the state for low-risk breast cancer treatment.
Why It Matters
The installation of ProSense® for breast cancer treatment at a major Alabama hospital indicates market expansion and potential revenue growth for IceCure Medical, positively impacting investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ICCM Stock
What is IceCure Medical Ltd.'s (ICCM) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, IceCure Medical Ltd. (ICCM) has a median price target of $3.13. The highest price target is $3.25 and the lowest is $3.00.
Is ICCM stock a good investment in 2026?
According to current analyst ratings, ICCM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICCM stock?
Wall Street analysts predict ICCM stock could reach $3.13 in the next 12 months. This represents a 353.6% increase from the current price of $0.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IceCure Medical Ltd.'s business model?
IceCure Medical Ltd. generates revenue through the sale of its cryoablation devices used in minimally invasive cancer treatments. The company targets healthcare providers, including hospitals and clinics, focusing on improving patient outcomes and safety while reducing recovery times. By offering a cutting-edge alternative to traditional surgical procedures, IceCure enhances its value proposition in the medical equipment market.
What is the highest forecasted price for ICCM IceCure Medical Ltd.?
The highest price target for ICCM is $3.25 from at , which represents a 371.8% increase from the current price of $0.69.
What is the lowest forecasted price for ICCM IceCure Medical Ltd.?
The lowest price target for ICCM is $3.00 from Yi Chen at HC Wainwright & Co., which represents a 335.5% increase from the current price of $0.69.
What is the overall ICCM consensus from analysts for IceCure Medical Ltd.?
The overall analyst consensus for ICCM is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.13.
How accurate are ICCM stock price projections?
Stock price projections, including those for IceCure Medical Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 11:50 AM UTC